Cedarburg Hauser Pharmaceuticals (CHP) has expanded the capacity of its Grafton active pharmaceutical ingredient (API) manufacturing plant.
The expansion efforts are a result of an increased demand for contract manufacturing of commercial APIs and are accompanied by additional upgrades aimed at improving safety and GMP systems.
Cedarburg Hauser chief executive officer Tony Laughrey said the expanded capacity will result in the hiring of 15 to 20 more employees over the next year.
“These improvements increase our total reactor capacity by nearly 50 percent,” said John Flahive, Cedarburg Hauser’s newly hired director of operations. “We have also added a reactor and chiller that allow for cryogenic reactions in our GMP labs.”
In addition to the new reactors, Cedarburg Hauser has also made improvements to the air handling systems in the GMP manufacturing suites, installed a reverse osmosis water system, improved isolation capabilities, and upgraded its Emerson DeltaV Digital Automation System.
“The added reactor capacity and upgrades to existing safety and GMP systems are the latest example of Cedarburg Hauser’s continued commitment to serving the commercial API marketplace,” Laughrey said. “The flexibility afforded by the additional reactor capacity allows us to better meet our customer’s on-time and on-budget requirements. We will continue to invest in our business as we strive to be the premier contract API manufacturer.”
